Bausch Health Companies Inc. (NYSE:BHC) Shares Sold by Tobam

Tobam trimmed its stake in Bausch Health Companies Inc. (NYSE:BHC - Free Report) by 91.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 22,215 shares of the company's stock after selling 225,735 shares during the quarter. Tobam's holdings in Bausch Health Companies were worth $179,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also made changes to their positions in the company. International Assets Investment Management LLC acquired a new position in Bausch Health Companies in the fourth quarter worth approximately $185,000. Thompson Investment Management Inc. lifted its position in Bausch Health Companies by 2.6% in the fourth quarter. Thompson Investment Management Inc. now owns 218,860 shares of the company's stock worth $1,755,000 after purchasing an additional 5,505 shares during the period. SG Americas Securities LLC bought a new position in Bausch Health Companies in the fourth quarter worth $555,000. Range Financial Group LLC bought a new position in Bausch Health Companies in the fourth quarter worth $649,000. Finally, Vanguard Group Inc. lifted its holdings in shares of Bausch Health Companies by 1.6% during the third quarter. Vanguard Group Inc. now owns 11,487,768 shares of the company's stock valued at $94,429,000 after acquiring an additional 175,489 shares during the period. 78.65% of the stock is owned by hedge funds and other institutional investors.

Bausch Health Companies Trading Up 0.5 %

Shares of NYSE:BHC traded up $0.04 during trading on Thursday, hitting $8.97. 15,231,962 shares of the company's stock traded hands, compared to its average volume of 2,770,659. Bausch Health Companies Inc. has a 52 week low of $5.57 and a 52 week high of $11.46. The company has a market cap of $3.28 billion, a price-to-earnings ratio of -5.53 and a beta of 0.85. The company has a 50-day moving average price of $9.21 and a 200-day moving average price of $8.13.

Bausch Health Companies (NYSE:BHC - Get Free Report) last released its quarterly earnings data on Thursday, February 22nd. The company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.01 by $0.14. Bausch Health Companies had a positive return on equity of 5,147.48% and a negative net margin of 6.76%. The business had revenue of $2.41 billion for the quarter, compared to analysts' expectations of $2.29 billion. During the same quarter in the previous year, the business posted $1.02 EPS. Bausch Health Companies's revenue for the quarter was up 9.8% on a year-over-year basis. On average, analysts predict that Bausch Health Companies Inc. will post 3.95 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. StockNews.com raised Bausch Health Companies from a "hold" rating to a "buy" rating in a report on Wednesday, February 7th. Royal Bank of Canada raised their target price on Bausch Health Companies from $9.00 to $12.00 and gave the company a "sector perform" rating in a research note on Friday, April 5th. Finally, Jefferies Financial Group lowered their target price on Bausch Health Companies from $16.00 to $14.00 and set a "buy" rating for the company in a research note on Tuesday, February 20th.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.